Ezra, a NYC-based startup creating a new way to screen for cancer, launched its prostate cancer screening program and announced a $4M seed round.
The round was led by Accomplice, with participation from Founders Future, Credo Ventures, Seedcamp, Esther Dyson and a number of startup founders and angel investors.
Led by Emi Gal, CEO & co-founder, and Diego Cantor, PhD, CTO and co-founder, the company provides a direct-to-consumer membership that offers men the ability to get a prostate MRI scan and have it analyzed by radiologists to help screen for cancer.
Currently available as an invite-only private beta program in New York City for $999 per year, Ezra is partnering with outpatient imaging company RadNet, Inc.. Ezra’s members will be able to get their prostate MRI scans at RadNet’s Lenox Hill Radiology facility in Manhattan (61 East 77th Street, New York, NY).
Additional facilities are scheduled to be enrolled through 2019.
The company is also developing artificial intelligence technology, the Ezra AI, designed to assist radiologists in their analysis and potentially make them more accurate and productive. it intends to seek marketing authorization from the FDA in 2019.
Ezra has R&D operations in Toronto.